326595-66-8

Usage

Uses

Used in Organic Synthesis:
4-Bromo-3-nitrobenzyl bromide is used as a building block in the synthesis of various biologically active compounds and pharmaceuticals. Its high reactivity allows it to react with various nucleophiles, enabling the preparation of diverse compounds such as benzyl bromides, nitrophenyl ethers, and other derivatives.
Used in the Preparation of 3-Substituted Coumarins:
4-Bromo-3-nitrobenzyl bromide is used as a reagent in the synthesis of 3-substituted coumarins, which are important heterocycles with a wide range of applications in pharmaceuticals, agrochemicals, and materials science.
Used in the Synthesis of Other Heterocycles:
Due to its versatility, 4-bromo-3-nitrobenzyl bromide is also employed in the preparation of other heterocycles, further expanding its applications in the field of organic chemistry and drug discovery.
Used in Pharmaceutical Industry:
As a key intermediate in the synthesis of various pharmaceuticals, 4-bromo-3-nitrobenzyl bromide plays a significant role in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-3-nitrobenzyl bromide is utilized in the synthesis of active ingredients for pesticides and other agrochemical products, contributing to the development of more effective and environmentally friendly solutions for crop protection.
Used in Materials Science:
4-Bromo-3-nitrobenzyl bromide is also employed in the synthesis of novel materials with unique properties, such as advanced polymers, dyes, and sensors, showcasing its potential in various applications beyond pharmaceuticals and agrochemicals.

InChI:InChI=1/C7H5Br2NO2/c8-4-5-1-2-6(9)7(3-5)10(11)12/h1-3H,4H2

Upstream product

• 5326-34-1 4-Bromo-3-nitrotoluene 
• 145547-97-3 (4-bromo-3-nitrophenyl)methanol 
• 163596-75-6 4-bromo-3-nitrobenzaldehyde 

Downstream Products

• 853180-68-4 2-bromo-5-acetoxymethylnitrobenzene 
• 851799-35-4 (E)-2',4',6'-trimethoxystyryl-4-bromo-3-aminobenzylsulfone 
• 1330633-74-3 (E)-2',4',6'-trimethoxystyryl-4-bromo-3-nitrobenzylsulfone 
• 1330633-54-9 4-bromo-3-nitrobenzylsulfonylacetic acid 
• 1330633-50-5 4-bromo-3-nitrobenzylthioacetic acid 
• 16096-32-5 4-methyl-1H-indole 
• 627487-97-2 N-methyl-2-(4'-acetoxymethyl-2'-nitrophenylthio)benzamide 
• 627487-40-5 2-[[4-[(acetyloxy)methyl]-2-nitrophenyl]thio]benzoic acid 
• 1026457-07-7 N-methyl-2-(4'-acetoxymethyl-2'-aminophenylthio)benzylamine 
• 853180-72-0 [3-amino-4-(2-methylaminomethyl-phenylsulfanyl)-phenyl]-methanol 

Relevant academic research and scientific papers

Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors

The PARP-2 selective inhibitor is important for clarifying specific roles of PARP-2 in the pathophysiological process and developing desired drugs with reduced off-target side effects. In this work, a series of novel quinazoline-2,4(1H,3H)-dione derivatives was designed and synthesized to explore isoform selective PARP inhibitors. As a result, compound 11a (PARP-1 IC50?=?467?nM, PARP-2 IC50?=?11.5?nM, selectivity PARP-1/PARP-2?=?40.6) was disclosed as the most selective PARP-2 inhibitor with high potency to date. The binding features of compound 11a within PARP-1 and PARP-2 were investigated respectively to provide useful insights for the further construction of new isoform selective inhibitors of PARP-1 and PARP-2 by using CDOCKER program.

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.

Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia

A dihydroquinolinone moiety was found to be a potent serotonin reuptake inhibitor pharmacophore when combined with certain amines. This fragment was coupled with selected D2 ligands to prepare a series of dual acting compounds with attractive in vitro profiles as dopamine D2 partial agonists and serotonin reuptake inhibitors. Structure-activity studies revealed that the linker plays a key role in contributing to D2 affinity, function, and SRI activity.

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2′-amino-4′-substituted-phenylthio)benzylamines: Potential candidates as selective serotonin transporter radioligands

A series of N,N-dimethylated and N-monomethylated analogues of N,N-dimethyl-2-(2′-amino-4′-iodophenylthio)benzylamine substituted at the 4′-phenyl position have been prepared and evaluated in vitro for serotonin transporter (SERT) selectivity. Several der